
|Articles|January 28, 2022
What’s New?
Acne patients are benefitting from a robust pipeline with treatments that hold promise for increased efficacy and safety. First-in-class additions to the FDA-approved armamentarium, such as the novel antiandrogen clascoterone (Winlevi; Sun Pharma), give dermatologists and pediatricians new tools to combat this skin condition. Speakers offer insights on matching medications to individual patient needs and controlling costs.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
ADA 2026 data highlight pediatric outcomes and treatment satisfaction with Afrezza
2
Dexcom Stelo cleared as first OTC continuous glucose monitor for children
3
Handheld optical device detects necrotizing enterocolitis in premature infants before radiographic signs appear
4
FDA approves lebrikizumab every-8-week maintenance dosing for moderate-to-severe atopic dermatitis
5

